Drug Trial Radar · NCT06901245
Tirzepatide in PWS, HO and GNSO
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Grace KimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vanderbilt University Medical Center; Children's Hospitals and Clinics of Minnesota; Seattle Children's Hospital
- First posted
- Mar 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 26 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Conditions
- Prader-Willi Syndrome
- Hypothalamic Obesity
- Obesity/Therapy
Interventions
TirzepatideDrug
Subjects will take Tirzepatide for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in weightTime frame: 48 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Children's Minnesota
Saint Paul, Minnesota · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.